{"filing":{"accession_number":"0001023024-26-000071","cik":"0001023024","ticker":"ANIP","company_name":"ANI PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-19","primary_document":"ani-20260819.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1023024/000102302426000071/ani-20260819.htm"},"events":[{"id":29040,"run_id":26573,"accession_number":"0001023024-26-000071","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses the appointment of Henry Gosebruch to ANI's Board of Directors effective August 19, 2026, with significant compensation details (initial restricted stock award of $525,000). While the filing also mentions Muthusamy Shanmugam's resignation as a director, the principal disclosed action centers on the board appointment of an experienced executive with deep M\u0026A and strategy expertise during a stated \"pivotal moment\" for the company's transformation. The appointment is material to investors given Gosebruch's track record and the company's strategic positioning.","company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":[{"id":31182,"accession_number":"0001023024-26-000071","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the appointment of Henry Gosebruch to ANI's Board of Directors effective August 19, 2026, with significant compensation details (initial restricted stock award of $525,000). While the filing also mentions Muthusamy Shanmugam's resignation as a director, the principal disclosed action centers on the board appointment of an experienced executive with deep M\u0026A and strategy expertise during a stated \"pivotal moment\" for the company's transformation. The appointment is material to investors given Gosebruch's track record and the company's strategic positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T11:02:39.364111+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31182,"accession_number":"0001023024-26-000071","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the appointment of Henry Gosebruch to ANI's Board of Directors effective August 19, 2026, with significant compensation details (initial restricted stock award of $525,000). While the filing also mentions Muthusamy Shanmugam's resignation as a director, the principal disclosed action centers on the board appointment of an experienced executive with deep M\u0026A and strategy expertise during a stated \"pivotal moment\" for the company's transformation. The appointment is material to investors given Gosebruch's track record and the company's strategic positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T11:02:39.364111+00:00","company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","filing_date":"2026-08-24"}]}